Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study
The 30% CFR improvement seen after 4 weeks of dapagliflozin persisted at 4 years, together with a significant reduction in EAT thickness, possibly explaining CFR improvement. Similar results in the placebo group after treatment strongly support a causal relationship and underscore the long-term CV benefits of dapagliflozin and its role in reducing CV risk in T2DM patients.
Authors
- Umberto Capece (ORCID: https://orcid.org/0000-0001-8048-8664)
- Domenico D’Amario (ORCID: https://orcid.org/0000-0003-3774-8330)
- Patricia Iozzo (ORCID: https://orcid.org/0000-0001-6443-7074)
- A. Guarneri (ORCID: https://orcid.org/0000-0001-6542-4953)
- Luigi Cappannoli (ORCID: https://orcid.org/0000-0002-6905-9268)
- Shawn Gugliandolo (ORCID: https://orcid.org/0000-0002-9656-4171)
- Teresa Mezza (ORCID: https://orcid.org/0000-0001-5407-9576)
- Francesca Cinti (ORCID: https://orcid.org/0000-0001-5170-7055)
- Andrea Giaccari (ORCID: https://orcid.org/0000-0002-7462-7792)
- Lucia Leccisotti (ORCID: https://orcid.org/0000-0002-6000-2898)
- A.W. Avolio (ORCID: https://orcid.org/0000-0003-2491-7625)
- Alfredo Pontecorvi (ORCID: https://orcid.org/0000-0003-0570-6865)
- Cassandra Morciano
- Francesco Burzotta (ORCID: https://orcid.org/0000-0002-6569-9401)
- Filippo Crea
- Maria Lucia Calcagni
- GianPio Sorice
- Amelia Splendore
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto di Fisiologia Clinica (IT)
- Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1186/s12933-025-02912-4
- Citations
- 5
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 6.94
Funders
- AstraZeneca
- Università Cattolica del Sacro Cuore